Chong Kun Dang Pharmaceutical Corp. has divulged glucagon-like peptide 1 receptor (GLP-1R) agonists potentially useful for the treatment of cardiovascular, endocrine, immunological, psychiatric, renal, inflammatory disorders, metabolic diseases and neurodegeneration.